Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.

Trial Details

NCT ID

NCT06782932

Phase

PHASE1 / PHASE2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

AGEN2373
Balstilimab
Cyclophosphamide
GVAX
AGEN2373 (RP2D)
mKRASvax

Locations (sample)

Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

Have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas.
Tumor must be deemed resectable by the study team
Patient's acceptance to have a tumor biopsy.
Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →